GUEST COLUMNISTS

• It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials

  Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

• Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy

  Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

• 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations

  Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

• What BriaCell's Trial Design Says About Real-World Cancer Research

  BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

• Accountability Gaps Can Break Clinical Supply Contracts

  Contract gaps can create clinical supply failures when responsibilities differ across agreements. See how aligning obligations can prevent costly disputes, delays, and risks.

• 'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint

  Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.

• Sustainable Patient Engagement: Your Enrollment And Representation Depend On It

  Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.

• Building The Execution Architecture For Real-World Data To Have Real-World Impact

  RWE's next challenge is execution. Learn how life sciences orgns can turn evidence into sustained business and clinical impact.